152 related articles for article (PubMed ID: 17526088)
1. Prevention of death in COPD.
La Vecchia C; Fabbri LM
N Engl J Med; 2007 May; 356(21):2211-2; author reply 2213-4. PubMed ID: 17526088
[No Abstract] [Full Text] [Related]
2. Prevention of death in COPD.
Duerden M
N Engl J Med; 2007 May; 356(21):2212; author reply 2213-4. PubMed ID: 17526087
[No Abstract] [Full Text] [Related]
3. Prevention of death in COPD.
Barnes PJ
N Engl J Med; 2007 May; 356(21):2211; author reply 2213-4. PubMed ID: 17522406
[No Abstract] [Full Text] [Related]
4. Prevention of death in COPD.
Kupfer Y; Tessler S
N Engl J Med; 2007 May; 356(21):2212-3; author reply 2213-4. PubMed ID: 17526086
[No Abstract] [Full Text] [Related]
5. [Chronic obstructive pulmonary disease. No increased survival with combination therapy].
Ecker-Schlipf B
Med Monatsschr Pharm; 2007 Nov; 30(11):428-9. PubMed ID: 18062342
[No Abstract] [Full Text] [Related]
6. Treatment of chronic obstructive pulmonary disease: Combination or component therapy?
Hackam DG
CMAJ; 2003 May; 168(10):1296-7. PubMed ID: 12743078
[No Abstract] [Full Text] [Related]
7. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
[No Abstract] [Full Text] [Related]
8. [Debates surrounding COPD].
Tillie-Leblond I; Housset B
Rev Mal Respir; 2010 Feb; 27(2):106-7. PubMed ID: 20206057
[No Abstract] [Full Text] [Related]
9. Fluticasone/salmeterol: labeling change.
Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
[TBL] [Abstract][Full Text] [Related]
10. Assessing mortality risk in COPD.
Richie RC
J Insur Med; 2008; 40(1):55-63. PubMed ID: 18924368
[No Abstract] [Full Text] [Related]
11. Combined salmeterol and fluticasone for COPD.
Vassiliou V
Lancet; 2003 May; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
[No Abstract] [Full Text] [Related]
12. The value of early diagnosis for effective management of chronic obstructive pulmonary disease.
Doherty DE; Chapman KR; Martinez FJ; Belfer MH
J Fam Pract; 2007 Oct; 56(10 Suppl Value):S1-24. PubMed ID: 17949606
[No Abstract] [Full Text] [Related]
13. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
Johnson M; Agusti AG; Barnes NC
COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
[TBL] [Abstract][Full Text] [Related]
14. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.
Vestbo J; Anderson JA; Calverley PM; Celli B; Ferguson GT; Jenkins C; Yates JC; Jones PW
Clin Respir J; 2011 Jan; 5(1):44-9. PubMed ID: 21159140
[TBL] [Abstract][Full Text] [Related]
15. Combined salmeterol and fluticasone for COPD.
Khamis RY; Rajakulasingam RK
Lancet; 2003 May; 361(9369):1652; author reply 1652-3. PubMed ID: 12747905
[No Abstract] [Full Text] [Related]
16. Choice of bronchodilator therapy for patients with COPD.
Wedzicha JA
N Engl J Med; 2011 Mar; 364(12):1167-8. PubMed ID: 21428773
[No Abstract] [Full Text] [Related]
17. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
[No Abstract] [Full Text] [Related]
18. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
19. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs.
Suissa S
Am J Respir Crit Care Med; 2008 Aug; 178(4):322-3. PubMed ID: 18676961
[No Abstract] [Full Text] [Related]
20. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
